Inhaled Biologics Face Significant Barriers Despite Pharmacokinetic Advantages for Respiratory Diseases

Treating respiratory diseases often requires targeted drug delivery to the lungs to maximize efficacy and minimize systemic side effects. While inhaled drugs are a cornerstone of therapy, the development of inhaled biologics (proteins, peptides, nucleic acids) presents unique challenges. These complex molecules are fragile and difficult to deliver efficiently to the lung parenchyma, leading to a gap between promising preclinical data and successful commercialization. Understanding these barriers is crucial for advancing novel therapeutic strategies for conditions like pulmonary hypertension and interstitial lung disease.

This comprehensive review synthesized findings from past and current clinical and preclinical studies on inhaled biologics for respiratory diseases. It analyzed both successful and discontinued development programs, identifying key lessons learned from their trajectories. The authors systematically examined the physical, biological, and technical barriers hindering the successful delivery of relatively fragile proteins, peptides, and nucleic acid therapeutics to the lung. Additionally, the review explored the commercial and clinical factors influencing the progression and ultimate commercialization of these products.

The review highlights an extensive developmental history for inhaled biologics, yet notes a limited number of products have reached commercialization despite the suitability of numerous disease states and targets for local lung delivery.

Significant physical, biological, and technical barriers must be overcome to successfully deliver fragile protein, peptide, or nucleic acid moieties to the lung. These barriers include issues like enzymatic degradation, mucociliary clearance, and poor epithelial permeability, which impact the bioavailability of inhaled therapeutics. Beyond technical hurdles, commercial and clinical reasons, such as high development costs and complex regulatory pathways, have also contributed to the lack of widespread success. However, the field is poised for rapid expansion, driven by the distinct pharmacokinetic advantages of the inhaled route for treating local lung diseases, promising more efficient drug action and reduced systemic exposure.